Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac007 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Yoshiya Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Lupus Nephritis, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zenyaku Kogyo Co., Ltd.
Abstract (Originalsprache)
Objectives
Although recommended in established international guidelines for lupus nephritis (LN), rituximab is not officially approved for LN treatment, making all such use off-label. The Japan College of Rheumatology (JCR) conducted a retrospective observational study on real-world efficacy and safety of rituximab treatment for LN in Japan.
Methods
Clinical data were collected from 47 hospitals for LN patients treated with rituximab to retrospectively investigate dosing schedule, efficacy, and safety.
Results
This retrospective analysis included 115 patients: 84 (73%) received 375 mg/m2 weekly up to four doses, and 31 (27%) received 1000 mg/body in one or two doses 2 weeks apart. Rituximab significantly improved findings for urinalysis, systemic lupus erythematosus serology, and systemic lupus erythematosus disease activity and was assessed as ‘extremely effective’ in 24.8% of patients and ‘effective’ in 60.2%. The renal response by the JCR-I criteria was 52.5% for overall response rate (ORR) (complete renal response rate 20.8% and partial renal response rate 31.7%) and that by the JCR-II criteria was 49.5% (21.8% and 27.7%, respectively). Corticosteroid dose was significantly reduced. Rituximab was well tolerated, with frequent but manageable adverse events of infusion reaction and infection.
Conclusions
Rituximab is effective for the treatment of Japanese patients with LN refractory to conventional therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
- Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan.
- Department of Rheumatology, Kobe City Medical Center General Hospital, Hyogo, Japan.
- Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan.
ORCID-Profile: Yoshiya Tanaka, Shingo Nakayamada, Kunihiro Yamaoka, Koichiro Ohmura, Shinsuke Yasuda
Förderung
- Zenyaku Kogyo Co., Ltd
Zitieren
APA
Tanaka, Y., Nakayamada, S., Yamaoka, K., Ohmura, K., & Yasuda, S. (2023). Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. Modern Rheumatology. https://doi.org/10.1093/mr/roac007
Vancouver
Tanaka Y, Nakayamada S, Yamaoka K, Ohmura K, Yasuda S. Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. Modern Rheumatology. 2023. doi:10.1093/mr/roac007
BibTeX
@article{Tanaka2023,
author = {Tanaka, Yoshiya and Nakayamada, Shingo and Yamaoka, Kunihiro and Ohmura, Koichiro and Yasuda, Shinsuke},
title = {Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac007}
}
EUVIMED